Member Info for PM2022

Val 201 partnership soon. Big News it will be. 14 million market cap where will this be heading.

Seems like a sensible move.

Val is what lies ahead, it is the future big move. SAR has done what it needed to do the smart ones will come here. We can see how fast Val goes up imagine when RNS arrives where it will go.

Not with the new board and the strategy in place to out license the drugs. This is where research comes in. The results for phase two came out late last year and they are working with Physiomics. Val 201 also possible treatment for Sepsis.

SAR is doing great. Looking to invest if it drops more so worth keeping an eye here. Not a cross ramp just feel Val in time will mirror SAR in some ways.

This will be massive. Partners looming. Perhaps news due any day regarding partner for Val 201. What a cheap entry point.

I missed out on this one but interesting to see where it goes..

Holding Valirx market cap only 11 million. 2 phase two drugs and looking for partners and Val 301 with Japanese also looking to partner. They seem very confident. Lots of meetings. That will be the next SAR in my opinion.

They need a nudge.

As Suzy and Kevin have always said they will choose the right partner.

When that news hits soon and with a current market cap 11 millions expect this to fly. Always buy low and sell high and what an entry point we have here.

Perhaps that is why it went from 4p to 74p last year.

That was also pre 201 results which had limitations but were positive therefore the asset is now worth more and we received significant funding at the time.

It can go lower but in my opinion not by much as it is not a true reflection of the assets that we have and two phase 2 drugs that we have not to mention Val 301. Based on market cap we should be at least about 40p now without any partner and I expect this to change considerably following partnership news.

11 million market cap.

Who wants a big multibag here. Can it really go much lower probably not.

Any decent news then off we go. We all know what is coming soon.

Got a funny feeling this will be a good week as it is long overdue.

Maybe 24-25 p by Friday without news and much more should something drop.

People suggesting some are selling to buy Sareum here. Market cap is now 159 million. It has more than 10 bagged in just over a year. For it to double from here market cap will need to be about 320 million. I wonder if the portfolio really justifies this market cap. Val market cap is 11 million which is nothing.

Sareum has not had any significant drop and I just see it dropping fast at some point. I will be doing some research and with anticipated results due any limitations then it could drop massively. Who remember when Val dropped from 74p to 22 on the same day. Sareum a possible short for me after results but it is all about timing and results. If it does not justify market cap then it should slump.

Someone on here suggested buying net scientific at 180 on last week and I did say not to buy due to significant spike and look where it went.

I think Val will go the same way as Sareun when a partnership is announced and could 4-10 bag from here easily over the next 12 months. A steady but significant rise like Sareum over many months. Always buy low, do research, be patient and sell high and for that reason Val will be a significant winning for me. Buying on spikes can make money but quiet often it goes back down significantly and that is why many lose on AIM. Therefore VAL at 11 million market cap is a big BUY for me.

Not much downside with a market cap of 11 million. Any positive news will see this rocket.

Yeah but the updates could not have been truthful that is why it was heading to zero.

We do need a good update though as it has been such a long time since a good RNS.

Buys showing up as sells.

It could well be. With a market cap of 3.34 trillion could turn out to be a nice deal.

Kidlington,

The Japanese pharma is unknown but I understand from reading from some of experts over the last few months in the industry it is one of the big ones.

https://www.businesswire.com/news/home/20200512005565/en/Pipeline-Review-for-Endometriosis---H1-2020---ResearchAndMarkets.com

Physiomics are doing work regarding all three drugs for 201, 301 and 401. I think 301 will most likely get a big deal if all goes well but that will most likely be later in the year. I think the big ones at the moment are 201 and 301 because they are stage 2 drugs looking for an immediate partner.

It will be big for Physiomics as well once those deals come through. I think both companies will see significant rise in the next 6 months. DYOR as always.

Morning

Thank you. A nice day today for sure some blue would be great. Agreed and hope this can move a little higher than the 20p we are currently on.

How many times does Suzy and Co have to say that 201 is a big priority for the company and to get this over the line asap. Physiomics will also want a deal done asap.

A deal will hit us any time as work is provided continuously to potential partners and with all the meetings that they had expect a deal anytime from now to November. I'm sure they would want the share price to be much higher before any potential dilution later in the year if one is needed.

November will be leaving it very late and the work will probably be finished much earlier than that date and not on that date as some seem to think on this board.

They mentioned the data modeling work that is being done and also they are helping to determine the maximum dosage for val 201 which was a limitation. They have meetings every two weeks with Physiomics who are presenting lots of work to help which will assist in getting us a great deal.

You can watch it on the Valirx website under investors then shareholder communication. May live Q and A. 1 hour but helps understand how valuable the work is.

The feedback for Physiomics has been very positive from Valirx and the work that is being done for all the drugs in the pipeline. During the online investor meeting last week it was made clear how valuable the work is. It was stated Val had meetings with over 40 different pharmaceuticals and is sharing data that Physiomics are working on.

I think many pharmaceuticals will be aware of the work and benefits that physiomics will give to any limitations from trials such as helping to determine the maximum dose such as in Val 201 and the potential value this work give. I think a great deal for Val 201 over the summer will kick start a great year here with many potential contracts coming offering royalties like with Val.